

# Nephrology Dialysis Transplantation



ISSN 0931-0509

Official Publication of the European Renal Association – European Dialysis and Transplant Association

Volume 13 Number 6 June 1998

## I. EDITORIAL FEATURES

### AWARD

1333

### MOLECULAR DETECTIVE STORIES

Identification of a gene for nephronophthisis  
F. Hildebrandt

1334

Autosomal dominant hypertension with brachydactyly:  
an enigmatic form of monogenic hypertension  
H. Schuster

1337

### EDITORIAL COMMENTS

Cell growth and cell death in renal distal tubules,  
associated with diuretic treatment  
B. Kaissling and J. Loffing

1341

Oxidative stress as the triggering event for vascular  
remodelling  
P. Silacci and D. Hayoz

1343

Goodpasture syndrome and end-stage renal failure —  
to transplant or not to transplant?  
K.-O. Netzer, F. Merkel and M. Weber

1346

Why are mutations in COL4A5 not detectable in all  
patients with Alport's syndrome?  
F. Flinter and K. Plant

1348

Glomerular involvement in Behçet's disease  
M. Benekli, I. C. Haznedaroğlu and Y. Erdem

1351

Microdomain structure of polymeric surfaces—Potential  
for improving blood treatment procedures  
R. Deppisch, H. Göhl and L. Smeby

1354

Does pre-operative duplex examination improve  
patency rates of Brescia-Cimino fistulas?  
M. S. Lemson, K. M. L. Leunissen and J. H. M. Tordoir

1360

Continuous renal replacement therapies in sepsis:  
where are the data?  
A. S. De Vriese, R. C. Vanholder, J. H. De Sutter,  
F. A. Colardyn and N. H. Lameire

1362

Honesty in publication  
A. M. Davison

1365

## PICTORIAL COMMENT

Podocytes and the development of segmental  
glomerulosclerosis  
M. Elger and W. Kriz

1368

## SPECIAL FEATURE

Skin cancers in transplant patients  
B. Dréno, E. Mansat, B. Legoux and P. Litoux

1374

## LAUDATIO AND FESTSCHRIFT

Laudatio for Professor Mary G. McGeown  
J. F. Douglas

1380

Primary and secondary uraemic hyperparathyroidism:  
from initial clinical observations to recent findings  
T. B. Drüeke

1384

Molly McGeown and renal transplantation  
P. J. Morris

1388

## II. SCIENTIFIC PAPERS

### ORIGINAL ARTICLES

Cytokine regulation of low-density lipoprotein receptor  
gene transcription in human mesangial cells  
X. Z. Ruan, Z. Varghese, R. Fernando and  
J. F. Moorhead

1391

Differentiating and proliferative effects of HGF in renal  
proximal tubular cells are mediated via different  
signalling pathways

S. Stracke, F. Ernst, D. R. Jehle, R. W. Grunewald,  
H. Haller, F. Keller and P. M. Jehle

1398

Comparative study of cyclosporin A, cyclosporin G, and  
the novel cyclosporin derivative IMM 125 in isolated  
glomeruli and cultured rat mesangial cells: a  
morphometric analysis

M. Potier, A. Wolf and J. Cambar

1406

Distinct regulation of IL-8 and MCP-1 by LPS and  
interferon- $\gamma$ -treated human peritoneal macrophages

K. Bauermeister, M. Burger, N. Almasreh, H. P. Knopf,  
R. R. Schumann, P. Schollmeyer and G. J. Dobos

1412

Modulation of transgene expression in mesothelial cells  
by activation of an inducible promoter

C. M. Hoff, J. L. Cusick, E. M. Masse, R. W. Jackman,  
J. A. Nagy and T. R. Shockley

1420

continued p. iv

Please do not forget to apply for the Training Course in  
Nephrology at the Rimini ERA-EDTA 35th Congress

Oxford University Press

# Abstracts

European Renal Association  
 European Dialysis and Transplant Association  
 Annual Congress,  
 Rimini, Italy  
 6-9 June, 1998

**LEGENDA:**

\* FIRST EIGHT  
 BEST ABSTRACTS  
 PRESENTED BY  
 YOUNG AUTHORS

■ FIRST EIGHT  
 BEST ABSTRACTS

Abstracts

**B: Renal metabolism, hormones, pharmacology**

**IMPORTANCE OF THE POTENTIAL LOAD OF ALKALI IN THE DIET OF THE RAT FOR ACID-BASE BALANCE**  
 1SH Lin, 1YF Lin, 2SC Dhadli, 2M Gowrishankar, 2ML Halperin  
 1Renal division, Tri-Service General Hospital, Taipei, Taiwan  
 2Renal division, St. Michael's Hospital, Toronto, Canada

To gain insights into the nature and physiology of endogenous acid production. Balance studies were performed for 24 hr; urine was collected separately in the day and night portion of the diurnal cycle. A low-electrolyte diet was fed to determine if dietary and urinary organic anions were similar in nature. A titration procedure was developed to gain insights into the pK of urinary unmeasured anions. Despite the fact that normal rats excreted net acid, this excretion was inversely related to the amount of food consumed. The rates of excretion of bicarbonate, citrate, and 'missing' anions were higher while that of net acid was lower in the night portion of diurnal cycle reflecting the net alkali load in the diet. When the dietary alkali removed by consuming a low-electrolyte diet, net acid excretion rose dramatically. Dietary and urinary organic anions were not identical in nature because rats fed the low alkali diet supplemented with potassium solely as its citrate salt excreted < 10% of this alkali load as citrate. When 3000 umol NH<sub>4</sub>Cl was given intraperitoneally, net acid excretion rose by close to 2000 uEq and the rate of excretion of anions with a pK in the 3-5 pH range fell by close to 1000 uEq; most of these changes occurred in the 7 hr after 3000 umol NH<sub>4</sub>Cl was given. Rat chow provided a net alkali load despite the fact that rats have an appreciable daily excretion of NH<sub>4</sub><sup>+</sup> and net acid. There are two types of endogenous acid production: the first example is sulphuric acid which requires a rise in net acid excretion for elimination of its proton load. The second example is dietary alkali-driven endogenous acid production which requires renal excretion of a family of organic anions to make these acids end-products of metabolism.

**RESULTS OF TREATMENT WITH REAFERON IN PATIENT WITH MESANGIOCAPILLARY GLOMERULONEPHRITIS (MCGN).**  
 A.N. Shishkin, A.V. Sosunov, V.I. Romanova, A.V. Volovnikova.  
 Therapeutic Department, Medical Faculty, State University of St. Petersburg;  
 Dep. of Microbiology, State Academy of Medicine, St. Petersburg; Laboratory of Influential Medicines, Institute of Influenza, St. Petersburg, Russia

It has been described that recombinant alfa-2 interferone is effective in treatment of virus associated glomerulonephritis resistant to the traditional therapy. We performed treatment with Reaferon(R) recombinant alfa-2 reafteron in 64 patients with different morphologic forms of glomerulonephritis who were serologically positive to some viruses ( HBV, Influenza, adenoidal-pharyngeal-conjunctival viruses, arthropod-borne virus and others). In this abstract we present only those results regarding to the treatment of one patient who underwent renal biopsy before and after treatment. A 56-year-old male patient with confirmed on biopsy MCGN manifested after the acute respiratory disease by hypertension, edema, nephrotic range proteinuria (5 gr/24hrs), hypoalbuminemia (35%), hypercholesterolemia (9,5 mmol/l) and serologically confirmed association with influenza virus A was treated with R. according to the traditional scheme. At the end of treatment decrease of proteinuria to 2 gr/24hrs, normalisation of protein levels, release of edema were noted. Within 9 months after treatment respiratory diseases were not noted, proteinuria was 3g/24hrs, glomerular filtration rate was 68 ml/min, total protein - 49g/l albumins-42%, serum cholesterol- 8,0mmol/l. Investigation of cellular immunity before treatment showed its suppression. After the course of R. indications of cellular immunity were improved. Repeated renal biopsy showed transformation of lobular form to the simple one, local sclerosis of stroma, partial glomerular glialinosis; diffuse segmental MCGN with minimal activity. After the repeated course of R. proteinuria was 1,3g/24hrs, glomerular filtration rate- 113ml/min, total protein - 60g/l, albumines - 48%, serum cholesterol 6,4mmol/l, indications of cellular immunity were at norm. In conclusion, this case is a good confirmation of the efficacy of recombinant alfa-2 interferon in glomerulonephritis associated with virus infection and it can be recommended as an alternative treatment to the traditional one. Also we can suppose the role of viruses in pathogenesis of glomerulonephritis.

**THE INFLUENCE OF rHuEPO THERAPY ON THYROID FUNCTION IN CHILDREN WITH END-STAGE RENAL FAILURE**

M. Roszkowska-Blaim, M. Sieniawska  
 Dep. of Pediatrics & Nephrology, University Children's Hospital, Warsaw, Poland

The aim of the study was to assess the influence of rHuEPO therapy on thyroid function in dialysed children. The study group comprised 19 children (11 on HD, 8 on CAPD), aged 4-17.5 years, mean 11.5±3.4. The period of renal replacement therapy was in HD group 1.5±0.75 years, in CAPD 2.7±1.4 years. All children had received sc rHuEPO in individually adjusted effective doses. When Hb was above 10g% (period I), rHuEPO was withdrawn, Hb was monitored every week and the therapy of rHuEPO was restarted when Hb decreased below 8 g% (period II). The interval between I and II periods was 5 to 14 weeks, mean 9.0±2.5. In all children, during the period I and II, the following parameters were estimated: thyrotropin (TSH), triiodothyronine (T<sub>3</sub>), thyroxine (T<sub>4</sub>).

Results: In most investigated children the values of T<sub>3</sub>, T<sub>4</sub> and TSH were normal in both periods.

Periods	T <sub>3</sub> [ng/ml]	T <sub>4</sub> [ng/ml]	TSH [μU/ml]
(Hb >10g%)	0.95±0.29 *	82.90±21.71 **	1.62±1.10
(Hb <8 g%)	1.19±0.31	59.21±19.41	1.71±1.54

\* T<sub>3</sub> (I) vs T<sub>3</sub> (II) p <0.01, \*\* T<sub>4</sub> (I) vs T<sub>4</sub> (II) p <0.001  
 Normal values: T<sub>3</sub> - 0.55 + 1.7 ng/ml, T<sub>4</sub> - 42 , 130 ng/ml,  
 TSH - 0.5 , 4.8 μU/ml

Conclusions: The mean values of T<sub>3</sub>, T<sub>4</sub> serum levels decreased significantly during the break of rHuEPO therapy, but were still in normal range. No changes in serum TSH levels were observed.

**FENOFIBRATE INCREASES CREATININEMIA BUT DOES NOT ALTER GLOMERULAR FILTRATION RATE IN PATIENTS WITH MILD RENAL INSUFFICIENCY.**

Hottelart C, El Esper N, Achard JM, Pruna A, Fournier A.  
 Service de Néphrologie, CHU Amiens, France.

Fenofibrate is a potent hypolipemic agent, widely used in patients with mild to severe renal failure in whom hyperlipoproteinemia is frequent. A moderate reversible increase in creatinine plasma levels has been reported with fenofibrate therapy; however, it is not known whether this increased creatininemia reflects a fenofibrate induced alteration of renal function or if fenofibrate interfere with creatinine tubular handling. We prospectively examined the effect of 2 weeks fenofibrate treatment (200 mg daily) on renal function in 13 hyperlipidemic patients with normal renal function or mild to moderate renal failure (Creat C1: 110 to 30 mVmin).

Results:	control	fenofibrate	p (paired)
t-test)			
plasma cholesterol	6.43±0.34	5.31±0.2	0.0004
plasma triglycerides	1.92±0.12	1.43±0.13	0.009
plasma creatinine	147±12 mmol/l	170±15 mmol/l	0.014
PAH clearance	304±56 ml/min	311±49 ml/min	NS
inulin clearance	51.7±6 ml/min	52.3±7 ml/min	NS
creatinine clearance	69±8 ml/min	68±8 ml/min	NS
24 h creatininuria	13.7±5 mmol	15.4±4 mmol	0.03

This study confirms that fenofibrate therapy significantly increases creatininemia in patients with mild to moderate renal failure, but does not alter renal hemodynamic nor glomerular filtration rate as assessed by the stability of PAH and inulin clearances. The increase in creatininemia is neither due to an inhibition of creatinine tubular excretion, since no change in creatinine clearance was observed, but appears to be associated to a parallel increase in creatinine daily urinary excretion.

Conclusions: fenofibrate therapy in renal patients does not worsen renal function, nor diminish the reliability of creatinine clearance for its follow-up in spite of a significant rise in creatininemia. The mechanism of the fenofibrate-induced increase in urinary creatinine excretion (increased metabolic production or decreased extra-renal elimination) remains to be determined.